Adolor tumbles on disappointing drug trial
559364
NEW YORK (CBS.MW) -- Adolor Corp. shares plunged as much as 47 percent Thursday, after the biopharmaceutical company said an advanced trial of a key gastrointestinal drug failed to meet its goals.
703528
Shares of Pharmos Corp.  fell 57 percent before the bell on Monday after the biopharmaceutical company said clinical trials showed its drug dexanabinol was not effective as a treatment for severe traumatic brain injury.
723080
Pfizer loses a patent case over its top compound.
455403
The biopharma announces a dramatic shift following the failure of its lead drug.
188476
Its unique compound to fight the growth of cancer cells fails in trials.
344028
Patients in trials of drug treatments are being left in the lurch when the research finishes, doctors say.
161543
Shares in pharmaceutical giants AstraZeneca PLC and GlaxoSmithKline PLC tumbled Friday after a US safety official raised concerns over key drugs sold by the companies.
429530
Shares of biotech firm Pharmos Corp. plunged 77 percent in premarket activity on Monday, after the company reported a late-stage trial of dexanabinol failed to demonstrate efficacy in treating severe traumatic brain injury.
495636
Shares of Advancis Pharmaceutical Corp. slid nearly 15 percent yesterday after the company said that the Food and Drug Administration had not accepted its application for a once-a-day version of the antibiotic amoxicillin.
677416
Rivals lead to lower sales of the pharmaceutical's only marketed drug.
426537
A "reckless" mistake caused the adverse reactions in the north London drug trial, according to an investigation.
497011
A multi-million pound drugs trial on a conspiracy to supply cocaine has collapsed at the Old Bailey.
556868
Efforts to develop a topical microbicide for use during sex suffered their second failure in a full-scale trial in recent years.
608577
EPIX Pharmaceuticals gets a qualified "yes" from the FDA, sending its stock tumbling.
431734
Drug manufacturer AstraZeneca PLC announced Friday that trials of its new lung cancer drug found it didn't help patients live longer. Its shares dropped more than 8 percent.
352529
Adolor will likely be waiting an extra three months for a decision on Entereg.
397855
Maxim Pharmaceuticals Inc.  said a trial to confirm the benefit of its Ceplene drug failed to show an improvement in survival rates for patients with liver cancer, sending its shares plunging on Monday.